Amy Dyken, controller at Oriole Pharmaceutical Industries, a
public company, is currently preparing the calculation for basic
and diluted earnings per share and the related disclosure for
Oriole’s financial statements. Below is selected financial
information for the fiscal year ended June 30, 2020.
Oriole Pharmaceutical Industries |
||
Long-term debt | ||
Notes payable, 9% |
$980,000 |
|
8% convertible bonds payable |
4,960,000 |
|
9% bonds payable |
5,940,000 |
|
Total long-term debt |
$11,880,000 |
|
Shareholders’ equity | ||
Preferred stock, 6% cumulative, $50 par value, 105,000 shares authorized, 26,250 shares issued and outstanding |
$1,312,500 |
|
Common stock, $1 par, 9,800,000 shares authorized, 980,000 shares issued and outstanding |
980,000 |
|
Additional paid-in capital |
4,020,000 |
|
Retained earnings |
5,930,000 |
|
Total shareholders’ equity |
$12,242,500 |
The following transactions have also occurred at Oriole.
1. | Options were granted on July 1, 2019, to purchase 220,000 shares at $16 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share. | |
2. | Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019. | |
3. | The preferred stock was issued in 2019. | |
4. | There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020. | |
5. | The 980,000 shares of common stock were outstanding for the entire 2020 fiscal year. | |
6. | Net income for fiscal year 2020 was $1,510,000, and the average income tax rate is 20%. |
For the fiscal year ended June 30, 2020, calculate the following
for Oriole Pharmaceutical Industries. (Round answers to
2 decimal places, e.g. $2.45.)
(a) Basic earnings per share____
(b) Diluted earnings per share____
Particulars | Calculations for the amounts | |
Calculation of Basic Earning per Share: | ||
Net Income after tax | 1,510,000 | |
Less: Preference Dividend | (78,750) | = 1312500*.06 |
Net Income for Common Shares | 1,431,250 | |
No. of Common Shares | 980,000 | = 980000/1 |
Basic Earnings per share | 1.460 | |
Calculation of Diluted Earning per Share: | ||
Calculation of No. Diluted Earnings: | ||
Net Income for Common Shares | 1,510,000 | From Part 1 Above |
Add: Income of Options (#1) | - | Nil |
Add: Income of Convertible Debentures | 317,440 | = 4960000 * 0.08 * (1-0.20) |
1,827,440 | ||
Calculation of No. Diluted Shares: | ||
Common Shares | 980,000 | From Part 1 Above |
Add: No. of Options (#1) | 44,000 | = 220000- (220000 * 16 / 20) |
Add: No. of Convertible Debentures | 248,000 | =4960000/1000*50 |
1,272,000 | ||
Diluted Earning per Shares | 1.437 | |
#1: For calculation of EPS, we calculate the number of options that are issued without any connsideration. Check the calculation as mentioned above. No consideration will be considered for the options so issued.
Final Note:
Since all the securitites are outstanding for the whole year, there is no need to calculate the weighted average number of outstanding securities.
Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,990,000 Total long-term debt $12,030,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan financial statements Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term diebt Notes payable, 10% 9X convertible bonds payable 10% bonds payable Total long-term debt $1.000.000 5,050,000 5.920,000 $11.970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% $1,020,000 9% convertible bonds payable 5,020,000 11% bonds payable 6,120,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Waterway Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Bridgeport Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Bridgeport’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Bridgeport Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $990,000 9% convertible bonds payable 5,040,000 10% bonds payable 6,080,000 Total long-term debt $12,110,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 4,970,000 10% bonds payable 5,980,000 Total long-term debt $11,970,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Monty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Monty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% 8% convertible bonds payable 11% bonds payable Total long-term debt $980,000 5,030,000 6,100,000 $12,110,000 Shareholders' equity Preferred stock, 6% cumulative,...